{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:26:36Z","timestamp":1768328796625,"version":"3.49.0"},"reference-count":27,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Eltrombopag, a thrombopoietin receptor agonist, is widely used in the treatment of relapsed or refractory (R\/R) immune thrombocytopenia (ITP). This study aimed to compare the efficacy, safety, and tolerability of generic eltrombopag (Rompag\u00ae) with original eltrombopag (Revolade\u00ae) in adult patients with R\/R ITP. Methods: In this prospective, multicenter study conducted at 10 centers, 104 adult ITP patients were followed for at least 3 months. A total of 35 (33.7%) patients received Rompag\u00ae and 69 (66.3%) received Revolade\u00ae. The primary endpoint was platelet (PLT) response, defined as achieving a PLT count \u226550 \u00d7 109\/L and at least a twofold increase from baseline, without the need for rescue therapy or transfusion. Secondary endpoints included bleeding rates, fatigue-related quality of life, adverse events (AEs), and rescue therapy requirements. Results: PLT response was achieved in 94.2% of patients in the Revolade\u00ae group and 85.7% in the Rompag\u00ae group (p = 0.16). Bleeding rates decreased significantly in both groups (Revolade\u00ae: 56.5% to 2.9%, p &lt; 0.001; Rompag\u00ae: 62.9% to 2.9%, p &lt; 0.001). Although overall AE rates were similar (30.4% in the Revolade\u00ae group and 42.9% in the Rompag\u00ae group; p = 0.22), arthralgia (28.6% vs. 7.2%, p = 0.01) and vomiting (11.4% vs. 0%, p = 0.008) were more frequent with Rompag\u00ae. Conclusions: Both generic and original eltrombopag demonstrated no statistically significant difference in efficacy in achieving PLT response, reducing bleeding, and improving fatigue-related quality of life in adult patients with R\/R ITP. Although minor differences in AE profiles were observed, particularly arthralgia and vomiting, both formulations showed acceptable safety and tolerability.<\/jats:p>","DOI":"10.3390\/jcm15020634","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T11:42:58Z","timestamp":1768304578000},"page":"634","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Original Versus Generic Eltrombopag in Patients with Immune Thrombocytopenia: A Prospective Multi-Center Experience on Efficacy and Safety"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1052-9800","authenticated-orcid":false,"given":"Serhat","family":"\u00c7elik","sequence":"first","affiliation":[{"name":"Department of Hematology, Yenimahalle Training and Research Hospital, Y\u0131ld\u0131r\u0131m Beyaz\u0131t University, Ankara 06370, T\u00fcrkiye"},{"name":"Department of Hematology, Faculty of Medicine, Ankara University, Ankara 06620, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep Tu\u011fba","family":"Karabulut","sequence":"additional","affiliation":[{"name":"Department of Hematology, Adana City Traning and Research Hospital, Adana 01370, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Selim","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mehmet Akif \u0130nan Traning and Research Hospital, \u015eanl\u0131urfa 63040, T\u00fcrkiye"},{"name":"Department of Hematology, Faculty of Medicine, Sel\u00e7uk University, Konya 42090, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5687-8531","authenticated-orcid":false,"given":"Rafiye","family":"\u00c7ift\u00e7iler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Sel\u00e7uk University, Konya 42090, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulkerim","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u00c7orum Erol Ol\u00e7ok Traning and Research Hospital, Hitit University, \u00c7orum 19040, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4081-1070","authenticated-orcid":false,"given":"Samet","family":"Yaman","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u00c7orum Erol Ol\u00e7ok Traning and Research Hospital, Hitit University, \u00c7orum 19040, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9907-1498","authenticated-orcid":false,"given":"\u0130brahim Ethem","family":"P\u0131nar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Isparta City Hospital, Isparta 32200, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-3127","authenticated-orcid":false,"given":"Ay\u015fe Hilal","family":"Ero\u011flu K\u00fc\u00e7\u00fckdiler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Adnan Menderes University, Ayd\u0131n 09100, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuray G\u00fcl","family":"A\u00e7ar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, \u00c7ukurova University, Adana 01330, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-5955","authenticated-orcid":false,"given":"Aysun","family":"\u015eent\u00fcrk Y\u0131k\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Denizli State Hospital, Denizli 20010, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0378-8687","authenticated-orcid":false,"given":"Vehbi","family":"Demircan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Dicle University, Diyarbak\u0131r 21280, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-3538","authenticated-orcid":false,"given":"Dilek","family":"Keskin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kanuni Sultan S\u00fcleyman Traning and Research Hospital, Istanbul 34303, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8657-1407","authenticated-orcid":false,"given":"\u0130brahim Halil","family":"A\u00e7ar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Osmaniye State Hospital, Osmaniye 80000, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-0434","authenticated-orcid":false,"given":"Ekin","family":"K\u0131rcal\u0131","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Medicana International Hospital, Ankara 06510, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meltem","family":"Kurt Y\u00fcksel","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Ankara University, Ankara 06620, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/JBM.S259101","article-title":"Management of adult patients with immune thrombocytopenia (ITP): A review on current guidance and experience from clinical practice","volume":"12","author":"Song","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0039-1700512","article-title":"Immune thrombocytopenia in adults: Modern approaches to diagnosis and treatment","volume":"46","author":"Kuter","year":"2020","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood.2021010968","article-title":"How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment","volume":"137","author":"Ghanima","year":"2021","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1182\/blood.V112.11.3432.3432","article-title":"Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura","volume":"112","author":"Bussel","year":"2008","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomized, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1538-7836.2012.04695.x","article-title":"A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia","volume":"10","author":"Tomiyama","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"key":"ref_9","unstructured":"U.S. Department of Health and Human Services (2025, October 04). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","article-title":"Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system","volume":"13","author":"Yellen","year":"1997","journal-title":"J. Pain Symptom Manag."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1182\/bloodadvances.2022008287","article-title":"Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: Final analysis of CITE","volume":"7","author":"Wong","year":"2023","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomized, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjh.14380","article-title":"Multicentre, randomized phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia","volume":"176","author":"Yang","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: Final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139967","article-title":"Eltrombopag for immune thrombocytopenia in adult patients in the real world in France: Final results of the ELEXTRA study","volume":"136","author":"Moulis","year":"2020","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-015-2556-z","article-title":"The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): A \u201creal life\u201d retrospective multicenter experience of the Rete Ematologica Pugliese (REP)","volume":"95","author":"Mazza","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MBC.0000000000000380","article-title":"Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: A retrospective study","volume":"27","author":"Eser","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_18","first-page":"240","article-title":"Real-world experience of eltrombopag in immune thrombocytopenia","volume":"10","author":"Mishra","year":"2020","journal-title":"Am. J. Blood Res."},{"key":"ref_19","first-page":"230","article-title":"A multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: A real-life experience","volume":"36","author":"Cekdemir","year":"2019","journal-title":"Turk. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12725","article-title":"Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice","volume":"97","author":"Pascual","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/17474086.2021.1995347","article-title":"Immune thrombocytopenia","volume":"14","author":"Bussel","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.13385","article-title":"Fatigue in immune thrombocytopenia","volume":"170","author":"Hill","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life","volume":"96","author":"Cooper","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajh.26045","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment","volume":"96","author":"Cooper","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.12169","article-title":"Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)","volume":"160","author":"Bussel","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2217\/cer-2019-0177","article-title":"Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists","volume":"9","author":"Forsythe","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10760296211005555","DOI":"10.1177\/10760296211005555","article-title":"Eltrombopag effectiveness and tolerability in chronic immune thrombocytopenia: A meta-analysis","volume":"27","author":"Ahmed","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/634\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T11:54:26Z","timestamp":1768305266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020634"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020634","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]}}}